Form D · Other
Conjupro Biotherapeutics Inc.
Princeton, NJ · CIK 0001993155
Offering snapshot reported Sep 12, 2023 · SEC filing
- Reported sold
- $9.32M Offering amount: $67.5M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 1, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 12, 2023 | Initial | $9,321,686 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-491870
Source: Form D, filed Sep 12, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Qingxi Wang | Director, Executive |
| Haixing Wang | Executive |
Issuer details
Industry: Other (See others in industry)
Address:
302 Carnegie Center Blvd, Suite 100
Princeton, NJ, 08540
Princeton, NJ, 08540